Posted on 27/01/2010 in Pharmaceutical Company Product News Almirall announced this week that it will halt its authorisation application for Eklira in the EU while it considers alternative dosing recommendations.
The outcome of a recent phase III trial into the chronic obstructive pulmonary disease (COPD) treatment displayed the benefits of its twice-daily (BID) administering.
As a result, the company will now give full priority to the development and filing of the BID dosing of Eklira (aclidinium bromide), putting on hold the filing of the once daily regimen.
Jorge Gallardo, president and chief executive officer of Almirall, commented: "This strategic decision has been taken following discussions with European regulatory experts and key opinion leaders from which it became clear that BID dosing is likely to provide a superior benefit for COPD patients."
Last week, Almirall highlighted the success of a psychiatry convergence which it recently hosted in Barcelona.
The meeting attracted over 300 experts in psychiatry and was the ninth event to be held so far. Other news stories from 27/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
